Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
University of Nebraska
Modality
nucleic_acid
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
57High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00736450CT.gov Oblimersen Sodium & Combination Chemotherapy in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma | — | Terminated | — | — | — |
NCT00086944CT.gov Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma | — | Completed | — | — | — |
NCT00080847CT.gov S0349 Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Oblimersen in Treating Patients With Advanced Diffuse Large B-Cell Non-Hodgkin's Lymphoma | — | Terminated | — | — | — |
NCT00060112CT.gov Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma | — | Terminated | — | — | — |
NCT00054639CT.gov Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Diffuse Large B-Cell Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Augmerosen (this asset) | University of Nebraska | P2 | BB · 65 |
| Vincristine Sulfate | National Cancer Institute (NCI) | P2/3 | BBB |
| Prednisone | Beth Israel Deaconess Medical Center | P4 | BBB |
| Adriamycin | Beth Israel Deaconess Medical Center | P4 | BBB |
| Cyclophosphamide | Beth Israel Deaconess Medical Center | P4 | BBB |
| Dexasone | Mwanasha Merrill, MD | P4 | BBB |
| Rituximab | Beth Israel Deaconess Medical Center | P4 | BBB |
| (+)-Vincristine | Beth Israel Deaconess Medical Center | P4 | BBB |
| Etoposide | The First Affiliated Hospital with Nanjing Medical University | P4 | BBB |
+42 more in the Diffuse Large B-Cell Lymphoma cohort
Other indications for Augmerosen
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Follicular Lymphoma | — | P2 | B · 62 |
| Mantle Cell Lymphoma | — | P2 | B · 62 |
| Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | — | P2 | B · 62 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Augmerosen in Diffuse Large B-Cell Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/augmerosen-diffuse-large-b-cell-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →